Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2002; 127(36): 1840
DOI: 10.1055/s-2002-33866
DOI: 10.1055/s-2002-33866
Pro & Contra
© Georg Thieme Verlag Stuttgart · New York
Chronische Hepatitis-C-Virusinfektion: immer behandeln! - Pro
Chronic hepatitis C virus infection: a general indication for treatment! - ProFurther Information
Publication History
eingereicht: 31.07.2002
akzeptiert: 21.08.2002
Publication Date:
05 September 2002 (online)
In der westlichen Welt sind 0,5-1,5 % der Bevölkerung chronisch mit dem Hepatitis C Virus (HCV) infiziert [1] . Trotz intensivierter Aufklärung in Laien- und Fachmedien sind in Deutschland wahrscheinlich weniger als 20 % der Infizierten diagnostiziert, d. h. die überwiegende Mehrheit der Betroffenen ist bislang nicht identifiziert.
Literatur
- 1 Zeuzem S, Roth W K, Herrmann G. Virushepatitis C. Z Gastroenterol. 1995; 33 117-32
- 2 Foster G R, Goldin R D, Thomas H C. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998; 27 209-212
- 3 Poynard T, Bedossa P, Opolon P. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups . Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997; 349 825-832
- 4 Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis. 1999; 19 263-269
- 5 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340 745-750
- 6 Sagmeister M, Renner E L, Mullhaupt B, Wong J B. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol. 2002; 14 25-34
- 7 Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns M P. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001; 345 1452-1457
- 8 Falck-Ytter Y, Kale H, Mullen K D, Sarbah S A, Sorescu L, McCullough A J. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002; 136 288-292
- 9 Hadziyannis S J, Cheinquer H, Morgan T, Diago M, Jensen D M, Sette H, Ramadori G, Bodenheimer H C, Marcellin P, Lee S -D, Roberts P J, Ackrill A M. Peginterferon alfa-2a (40KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol. 2002; 36 (Suppl 1) 3
- 10 Manns M P, McHutchison J G, Gordon S C, Rustgi V K, Shiffman M, Reindollar R, Goodman Z D, Koury K, Ling M, Albrecht J K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358 958-965
- 11 Fried M W, Shiffman M L, Reddy R K. et al . Pegylated (40 kDa) interferon alfa-2a (Pegasys) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Gastroenterology. 2002; 120 (Suppl 1) A55
- 12 Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001; 34 593-602
Prof. Dr. med. Stefan Zeuzem
Direktor der Klinik für Innere Medizin II, Universitätskliniken
des Saarlandes
66421 Homburg/Saar
Phone: 06841/16-23201
Fax: 06841/16-23267
Email: zeuzem@uniklinik-saarland.de